Immunotherapy of Hepatocellular Carcinoma by Hepatic Intra Arterial Injection of Autologous Gamma-delta T Lymphocytes: A Phase I Study
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Onset of: thrombosis of hepatic artery, grade 4 liver toxicity, or grade 3 or more allergic, neurological, dermatological, infectious, or respiratory reaction
Within 14 days after treatment
Yes
Jean-Luc RAOUL, MD, PhD
Principal Investigator
CRLCC Eugène Marquis, Rennes
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
ID RCB 2007-A00249-44
NCT00562666
February 2008
January 2009
Name | Location |
---|